Abbott Laboratories stock outperforms competitors on strong trading day
Shares of Abbott Laboratories rose 4.62% to $123.22 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.53% to 6,118.71 and the Dow Jones Industrial Average rising 0.
Barclays raises Abbott Labs stock price target to $158
Barclays (LON:BARC) analyst Matt Miksic increased the price target on Abbott Labs (NYSE:ABT) shares to $158 from $149, while reiterating an Overweight rating on the stock. The adjustment comes in light of management's updated financial outlook and the analyst's revised earnings estimates,
What’s Driving Abbott Laboratories (ABT) Stock’s 9.45% Surge Over the Past Month?
Oppenheimer has recently initiated Abbott Laboratories (ABT) stock to Outperform rating, as announced on October 8, 2024, according to Finviz. Earlier, on September 19, 2024, Piper Sandler had initiated the stock to Overweight,
Abbott Laboratories Will Outperform Healthcare Stocks in 2025
The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter, Abbott Laboratories outperformed and has a more robust outlook.
Abbott Laboratories' SWOT analysis: stock poised for growth amid challenges
Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to InvestingPro data,
Why Is Abbott Laboratories (ABT) Stock Surpassing 6.96% from Its 50-Day SMA?
Oppenheimer has recently initiated Abbott Laboratories (ABT) stock to Outperform rating, as announced on October 8, 2024, according to Finviz. Earlier, on September 19, 2024, Piper Sandler had initiated the stock to Overweight,
Barclays Remains a Buy on Abbott Laboratories (ABT)
In a report released today, Matt Miksic from Barclays maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price ...
Abbott Labs' Ensure, made in Columbus, hits multibillion-dollar milestone
A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...
Abbott pushes toddler milks that can cause health issues: lawsuit
The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.
Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Abbott Laboratories (NYSE: ABT) Q4 2024 Earnings Call Jan 22, 2025, 9:30 a.m. ET ...
Crain's Chicago Business12d
Lawsuit accuses Abbott of marketing 'ploy' for its 'toddler milk'
The organization that filed the proposed class action alleges marketing for the product tricks parents of young children who ...
Abbott Laboratories: Strong Performance and Promising Outlook Support Buy Rating
Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...
Abbott sued over its marketing of potentially harmful toddler milk
Formulas marketed for toddlers are a burgeoning business, but pediatricians have long recommended against their use.
Abbott banks on glucose monitors, new launches to ride out China, currency hit
(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects ...
Paul MacDonald's Past Picks: Stryker, Abbott Laboratories and Elevance Health
Paul MacDonald, CIO and portfolio manager at Harvest Portfolios Group Focus, shares his past picks; Stryker, Abbott ...